权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Targeting MLL/Menin in AML

AML 中的目标 MLL/Menin

基本信息

批准号：
10220875
负责人：
SCOTT A ARMSTRONG
金额：
$ 2.05万
依托单位：
DANA-FARBER CANCER INST
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-09-19 至 2023-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10220875
关键词：
Acute Myelocytic Leukemia Apoptosis Azacitidine Biological Biological Markers Biological Models Biotechnology Bromodomain Cell Differentiation process Cell Proliferation Cells Chromatin Chromosome Structures Clinical Clinical Research Clinical assessments Complex Development Doctor of Medicine Doctor of Philosophy EZH2 gene Enzyme Activation FLT3 gene FLT3 inhibition FLT3 inhibitor Foundations Future Gene Expression Gene Rearrangement Genes Genetic HOXA9 gene Hematopoietic Histones Homeobox Genes In Vitro KDM1A gene Lead Leukemic Cell MEIS1 gene MLL gene MLL-rearranged leukemia Maintenance Menin Modeling Multiprotein Complexes Mutation Myeloproliferative disease NPM1 gene Patients Pharmaceutical Preparations Phase I Clinical Trials Process Proteins Receptor Protein-Tyrosine Kinases Refractory Relapse Resistance Therapeutic Time Translating Work acute myeloid leukemia cell base cell growth early phase clinical trial early phase trial experimental study functional genomics in vivo inhibitor/antagonist leukemia leukemia relapse mouse model mutant patient derived xenograft model phase I trial preclinical study programs protein complex resistance mechanism response small molecule small molecule inhibitor transcription factor treatment strategy

项目摘要

Abstract: Inappropriate expression of genes such as the homeotic (HOX) genes is found in up to 40% of cases of Acute Myelogenous Leukemia (AML). Two well-known genetic subsets, those with MLL-rearrangements and those with NPM1 mutations, are known to possess high-level expression of HOX genes and have been shown to be dependent on continued expression of these genes. Recent studies have defined the protein complexes that maintain this aberrant gene expression. Furthermore, multiple groups and pharma/biotech companies have now developed small molecule inhibitors of these complexes. Some of these small molecules, particularly those targeting DOT1L, EZH2 and Bromodomains) have recently entered early phase trials and have shown interesting biological and some complete clinical responses. Another approach to target chromatin associated complexes is inhibition of the MLL1-Menin interaction, an approach that has also been shown to reverse HOX gene expression. In this proposal we will characterize newly developed MLL1-Menin inhibitors and work to bring one of these small molecules to clinical assessment. In Specific Aim 1 we will characterize the effects on gene expression and chromatin state after inhibition of the MLL1-Menin interaction in MLL-rearranged and NPM1 mutant AML cells. In Specific Aim 2 we will assess the combination of MLL1-Menin inhibitors with either azacitidine, DOT1L inhibitors or FLT3 inhibitors. In Specific Aim 3 we will initiate a phase 1 trial of MLL-1 Menin inhibitors alone and in combination with a azacitidine. These trials that will set the foundation for further assessment of combinations based on results from preclinical studies described here. The proposed experiments will propel MLL1-Menin inhibitors to clinical assessment and importantly define combination approaches that should be assessed in future clinical studies.

文摘: